Tianshili (600535.SH) subsidiary obtains registration certificate for Bosentan dispersible tablets drug.

Zhijian Finance APP News, Tasly (600535.SH) announced that recently, its wholly-owned subsidiary Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (referred to as "Jiangsu Diyi") received the approved and issued Drug Registration Certificate for Bosentan Dispersible Tablets from the National Medical Products Administration. The indications for this drug are pulmonary arterial hypertension (PAH) (WHO Group 1): used to improve pulmonary vascular resistance (PVR) in pediatric idiopathic or congenital PAH patients aged 3 years; used to treat adult patients with WHO functional class II-IV pulmonary arterial hypertension (PAH) (WHO Group 1).